普拉德威利综合征成人的生物年龄评估 (ETABIOLPWS) (ETABIOLPWS)
接受综合多学科代谢康复计划的 Prader-Willi 综合征成人的生物年龄评估
The primary objective of the study is to compare, in a cohort of obese subjects with PWS hospitalized at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy, the age acceleration calculated at study entry (T0) with the age acceleration measured at the end of a 3-week multidisciplinary metabolic rehabilitation program (T1).
Secondary objectives are to correlate the biological age with the anthropometric characteristics (with particular reference to the body composition), the glycometabolic picture, the main parameters and cardiovascular risk factors, the therapy (previous and concomitant) with rhGH and the cognitive function (mainly, the IQ).
研究概览
详细说明
Methods Thirty adults affected by clinically diagnosed and genetically confirmed PWS are recruited, regardless of the treatment (previous or concomitant) with rhGH (F/M = 15/15; age: ≥ 18 years; BMI > 35 kg/m2), hospitalized for a period of integrated multidisciplinary metabolic rehabilitation at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy.
After verifying the inclusion criteria, clinical and anthropometric data will be collected, including the evaluation of body composition with bioimpedance analysis. Cognitive function will be assessed with a psychometric scale (Wechsler Adult Intelligence Scale).
Blood samples will be taken from each patient upon admission to the hospital (T0) and after 3 weeks of rehabilitation hospitalization (at the same time to reduce circadian variability) for the determination of the basal glycometabolic profile (glucose, insulin, HOMA-IR, glycated Hb , triglycerides, total cholesterol, LDL, HDL, and hsPCR), as well as circulating levels of leptin, IL-6, and TNF-α.
The samples taken will be used for DNA extraction. DNA methylation will be performed by treatment with sodium bisulphite and PCR-Pyrosequencing.
Biological age measurement Biological (epigenetic) age will be measured using the two algorithms of Zbiec-Piekarska (9) and Daunay (10), based on the level of DNA methylation in specific gene loci. To have an estimate of the epigenetic (biological) age that is independent of the chronological age, we will use a measure defined as age acceleration, from which, with statistical inference, we will calculate the age acceleration. To calculate it, a linear regression model with the chronological age as the independent variable and the epigenetic age as the dependent variable will be applied; the difference between the observed value and the one predicted by the model will constitute the age acceleration due to epigenetic effects. In the event that the epigenetic age is greater than the chronological age, the age acceleration will have a positive value expressed in years, negative if vice versa.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Verbania
-
Oggebbio、Verbania、意大利、28824
- Istituto Auxologico Italiano IRCCS, Site Piancavallo
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult patients with Prader-Willi syndrome with BMI > 35 kg/m2
描述
Inclusion Criteria:
- adult patients with PWS, clinically diagnosed and genetically confirmed, regardless of rhGH treatment (previous or concomitant)
- age: ≥ 18 years
- BMI > 35 kg/m2
- hospitalization for integrated multidisciplinary metabolic rehabilitation program
Exclusion Criteria:
- age < 18 years
- BMI < 35 kg/m2
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
DNA methylation
大体时间:Baseline and at the end of the rehabilitation program (21 days)
|
Change in level of DNA methylation |
Baseline and at the end of the rehabilitation program (21 days)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Glycometabolic profile: glucose
大体时间:Baseline and at the end of the rehabilitation program (21 days)
|
Change in glycometabolic profile - glucose levels |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Glycometabolic profile: insulin
大体时间:Baseline and at the end of the rehabilitation program (21 days)
|
Change in glycometabolic profile - insulin levels |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body fat mass
大体时间:Baseline and at the end of the rehabilitation program (21 days)
|
Change in body fat mass - bioimpedance analysis |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body fat free mass
大体时间:Baseline and at the end of the rehabilitation program (21 days)
|
Change in body fat free mass - bioimpedance analysis |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body weight
大体时间:Baseline and at the end of the rehabilitation program (21 days)
|
Change in body weight |
Baseline and at the end of the rehabilitation program (21 days)
|
|
Body mass index
大体时间:Baseline and at the end of the rehabilitation program (21 days)
|
Change in body mass index |
Baseline and at the end of the rehabilitation program (21 days)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.